Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -60.77% | -65.93% | -73.89% | -67.24% | -64.31% |
| Total Receivables | 10.58% | 28.74% | 22.40% | -9.84% | 40.64% |
| Inventory | 51.90% | 39.14% | 20.55% | 12.48% | 12.84% |
| Prepaid Expenses | 19.10% | -29.66% | -22.40% | -8.63% | 0.63% |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | -33.32% | -43.45% | -57.65% | -55.60% | -53.06% |
|
|
|||||
| Total Current Assets | -33.32% | -43.45% | -57.65% | -55.60% | -53.06% |
| Net Property, Plant & Equipment | 21.27% | 286.22% | 175.95% | 179.85% | 140.06% |
| Long-term Investments | -5.44% | -3.99% | -7.73% | 170.40% | 138.16% |
| Goodwill | -5.44% | -3.99% | -7.73% | 170.40% | 138.16% |
| Total Other Intangibles | -6.14% | -5.07% | -9.75% | 567.90% | 469.00% |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 3.15% | -12.68% | -13.25% | 52.83% | 35.33% |
| Total Assets | -10.29% | -6.66% | -21.47% | 39.38% | 24.71% |
|
|
|||||
| Total Accounts Payable | -38.25% | 39.18% | -46.21% | 49.70% | 23.62% |
| Total Accrued Expenses | 158.86% | 89.89% | 97.77% | -33.18% | 14.09% |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -18.90% | 24.41% | -54.13% | -45.82% | -52.91% |
| Total Finance Division Other Current Liabilities | 85.48% | -22.67% | -39.00% | -35.72% | -30.15% |
| Total Other Current Liabilities | 85.48% | -22.67% | -39.00% | -35.72% | -30.15% |
| Total Current Liabilities | 1.25% | 16.81% | -39.79% | -11.11% | -11.74% |
|
|
|||||
| Total Current Liabilities | 1.25% | 16.81% | -39.79% | -11.11% | -11.74% |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 53.05% | 2,675.45% | 1,142.00% | 993.07% | 619.24% |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -10.87% | -8.56% | -12.78% | 654.40% | 517.90% |
| Total Liabilities | 10.17% | 61.68% | 2.99% | 132.68% | 102.63% |
|
|
|||||
| Common Stock & APIC | -0.23% | -0.56% | -2.39% | 33.92% | 28.24% |
| Retained Earnings | -23.05% | -33.59% | -48.46% | -54.86% | -51.12% |
| Treasury Stock & Other | 180.96% | 131.66% | 204.41% | 197.38% | -61.09% |
| Total Common Equity | -17.25% | -20.80% | -27.44% | 22.24% | 10.28% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -17.25% | -20.80% | -27.44% | 22.24% | 10.28% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -17.25% | -20.80% | -27.44% | 22.24% | 10.28% |
|
|
|||||